{"id":"cefazolin-postoperatively","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Hypersensitivity reactions (rash, urticaria)"},{"rate":"1-2","effect":"Phlebitis at injection site"},{"rate":"1-2","effect":"Diarrhea"},{"rate":"0.5-1","effect":"Nausea"},{"rate":"0.01-0.1","effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL1200523","moleculeType":"Small molecule","molecularWeight":"476.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It is bactericidal and has broad activity against gram-positive cocci and some gram-negative bacteria. When used postoperatively, it provides prophylaxis against surgical site infections.","oneSentence":"Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:11.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis (postoperative use)"},{"name":"Bacterial infections caused by susceptible organisms"}]},"trialDetails":[{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":"Arthropathy of Knee, Antibiotic Prophylaxis","enrollment":1770},{"nctId":"NCT02285140","phase":"NA","title":"Prevention of Infections in Cardiac Surgery","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2015-04","conditions":"Thoracic Surgery, Antibiotic Prophylaxis","enrollment":5989},{"nctId":"NCT04079686","phase":"NA","title":"Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty","status":"COMPLETED","sponsor":"Daniela Francescato Veiga","startDate":"2019-08-04","conditions":"Plastic Surgery, Mammaplasty, Anti-bacterial Agents","enrollment":146},{"nctId":"NCT06791993","phase":"PHASE4","title":"Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Acibadem Maslak Hospital","startDate":"2025-02-01","conditions":"Dysbiosis, Gut -microbiota, Microbiome Analysis","enrollment":60},{"nctId":"NCT06189885","phase":"NA","title":"Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-08-01","conditions":"Periprosthetic Joint Infection","enrollment":184},{"nctId":"NCT04834310","phase":"PHASE4","title":"Postoperative Antibiotics Following Primary and Secondary Breast Augmentation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":"Surgical Site Infection, Capsular Contracture Associated With Breast Implant, Antibiotic Resistant Infection","enrollment":""},{"nctId":"NCT04577846","phase":"PHASE3","title":"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-11-01","conditions":"Surgical Site Infection","enrollment":384},{"nctId":"NCT00550290","phase":"PHASE4","title":"Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy","status":"COMPLETED","sponsor":"Aultman Health Foundation","startDate":"2007-10","conditions":"Wound Infection","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":185,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ancef","Kefzol"],"phase":"marketed","status":"active","brandName":"Cefazolin PostOperatively","genericName":"Cefazolin PostOperatively","companyName":"Aultman Health Foundation","companyId":"aultman-health-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis (postoperative use), Bacterial infections caused by susceptible organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}